A “slow and steady wins the race” mindset is not one usually seen in venture finance.
Typically, funds want to deploy cash quickly, see results and make an exit – oftentimes within five years.
Investing In Digital: Slow And Steady May Win This Race
Listen to this article
Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.
Candid conversations with C-suite leaders.
More from Deal-Making
• By
<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>
• By
China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”
• By
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
• By
An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
